These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34971322)

  • 1. Quantifying Input Behaviors That Influence Clinical Outcomes in Diabetes and Other Chronic Illnesses.
    Lewis DM
    J Diabetes Sci Technol; 2022 May; 16(3):786-787. PubMed ID: 34971322
    [No Abstract]   [Full Text] [Related]  

  • 2. How It Started, How It Is Going: The Future of Artificial Pancreas Systems (Automated Insulin Delivery Systems).
    Lewis D
    J Diabetes Sci Technol; 2021 Nov; 15(6):1258-1261. PubMed ID: 34218717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Future of Automated Insulin Delivery (AID) Systems.
    Garg SK; McVean JJ
    Diabetes Technol Ther; 2024 Mar; 26(S3):1-6. PubMed ID: 38377322
    [No Abstract]   [Full Text] [Related]  

  • 4. [What is the current state of the artificial pancreas in diabetes care?].
    Dimou M; Laimer M; Stettler C; Bally L
    Internist (Berl); 2020 Jan; 61(1):102-109. PubMed ID: 31863132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated Insulin Dosing Systems or Automated Insulin Delivery Systems? It is Time for Consistency.
    Klonoff DC; Shang T; Zhang J
    J Diabetes Sci Technol; 2021 Mar; 15(2):211-213. PubMed ID: 33650456
    [No Abstract]   [Full Text] [Related]  

  • 6. Current Status and Emerging Options for Automated Insulin Delivery Systems.
    Forlenza GP; Lal RA
    Diabetes Technol Ther; 2022 May; 24(5):362-371. PubMed ID: 35099302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the Interoperable Artificial Pancreas System for Type 1 Diabetes Management During Psychological Stress.
    Pinsker JE; Deshpande S; McCrady-Spitzer S; Church MM; Kaur RJ; Perez J; Desjardins D; Piper M; Reid C; Doyle FJ; Kudva YC; Dassau E
    J Diabetes Sci Technol; 2021 Jan; 15(1):184-185. PubMed ID: 32783473
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Advanced Hybrid Closed-Loop System in a Patient with Pancreas Cancer.
    Hacisahinogullari H; Caklili OT; Saribeyliler G; Rasulova N; Selcukbiricik O; Gul N; Uzum AK; Karsidag K
    Diabetes Technol Ther; 2022 Sep; 24(9):675-676. PubMed ID: 35349364
    [No Abstract]   [Full Text] [Related]  

  • 10. Who needs an artificial pancreas? (？).
    Winikoff J; Drexler A
    J Diabetes; 2013 Sep; 5(3):254-7. PubMed ID: 23601378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-source automated insulin delivery in type 1 diabetes-the evidence is out there.
    Hussain S; Lal RA; Braune K
    Lancet Diabetes Endocrinol; 2022 Dec; 10(12):835-836. PubMed ID: 36244346
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparing the technical reliability and insulin dosing of a "do-it-yourself artificial pancreas" with a commercial hybrid closed-loop system in a "shadow-mode" scenario: An exploratory study.
    Künzler J; Züger T; Stettler C; Laimer MW; Melmer A
    Diabetes Obes Metab; 2023 Sep; 25(9):2780-2783. PubMed ID: 37311723
    [No Abstract]   [Full Text] [Related]  

  • 13. Do-It-Yourself Automated Insulin Delivery: A Position Statement.
    ; Halperin IJ; Chambers A; Covello L; Farnsworth K; Morrison AE; Schuklenk U; Witteman HO; Senior P; ; Bajaj HS; Barnes T; Gilbert J; Honshorst K; Kim J; Lewis J; MacDonald B; Mackay D; Mansell K; Rabi D; Senior P; Sherifali D
    Can J Diabetes; 2023 Jul; 47(5):381-388. PubMed ID: 37532365
    [No Abstract]   [Full Text] [Related]  

  • 14. Errors of commission or omission: The net risk safety analysis conversation we should be having around automated insulin delivery systems.
    Lewis DM
    Diabet Med; 2022 May; 39(5):e14687. PubMed ID: 34510544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human-in-the-Loop Insulin Dosing.
    Bequette BW
    J Diabetes Sci Technol; 2021 May; 15(3):699-704. PubMed ID: 31801361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where Do We Stand with Closed-Loop Systems and Their Challenges?
    Jackson M; Castle JR
    Diabetes Technol Ther; 2020 Jul; 22(7):485-491. PubMed ID: 32069100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large Treatment Effects With Automated Insulin Delivery System.
    Slomski A
    JAMA; 2022 Oct; 328(16):1581-1582. PubMed ID: 36282258
    [No Abstract]   [Full Text] [Related]  

  • 18. Automated Insulin Delivery in Real Life (AID-IRL): Real-World User Perspectives on Commercial AID.
    Lewis D
    J Diabetes Sci Technol; 2022 Mar; 16(2):500-503. PubMed ID: 32935554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Ambulatory Glucose Profile in Patients With Type 1 Diabetes Mellitus After Switching From Sensor-Augmented Insulin Pump Therapy to a Do-It-Yourself Artificial Pancreas System: A Retrospective Data Analysis of Real-World Data.
    Müller-Korbsch M; Frühwald L; Kietaibl A
    J Diabetes Sci Technol; 2022 Nov; 16(6):1577-1579. PubMed ID: 35915931
    [No Abstract]   [Full Text] [Related]  

  • 20. Real world evidence of the efficacy of two hybrid closed loop systems for children and adults with type 1 diabetes with some clinical warnings.
    Henry Z; Villar Fimbel S; Bendelac N; Thivolet C
    Diabetes Metab; 2022 Nov; 48(6):101396. PubMed ID: 36252880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.